Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction

Circulation

Volumn 108, Issue 1, 2003, Pages 92-96

  Benítez, Sonia ^a   Sánchez Quesada, José Luis ^a   Ribas, Vicent ^a   Jorba, Oscar ^a   Blanco Vaca, Francisco ^a   González Sastre, Francesc ^a   Ordóñez Llanos, Jordi ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Fatty acids; Inflammation; Lipoproteins

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; FATTY ACID; LOW DENSITY LIPOPROTEIN;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FAMILIAL HYPERCHOLESTEROLEMIA; FRACTIONATION; HUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; WESTERN BLOTTING;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BLOTTING, WESTERN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME ACTIVATION; FATTY ACIDS, NONESTERIFIED; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION; LIPOPROTEINS, LDL; PHOSPHOLIPASES A; REFERENCE VALUES;

EID: 17344394888     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000072791.40232.8F     Document Type: Article

References (30)

1. Stafforini DM, McIntyre TM, Zimmerman GA, et al. Platelet-activating factor acetylhydrolases. J Biol Chem. 1997;272:17895-17898.
2. Macphee CH, Milliner K, Moores KE, et al. The involvement of LDL-associated phospholipase A2 in atherogenesis. Pharmacol Rev Commun. 1996;8:309-315.
3. Macphee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioacfive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999;338:479-487.
4. Packard CJ, O'Reilly CSJ, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med. 2000;343:1148-1155.
5. Caslake MJ, Packard CJ, Suckling KE, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary heart disease. Atherosclerosis. 2000;150:413-419.
6. Leach CA, Hickey DM, Ife RJ, et al. Lipoprotein-associated phospholipase A2 inhibition: a novel, non-lipid lowering strategy for atherosclerosis therapy. Farmaco. 2001;56:45-50.
7. de Castellarnau C, Sánchez-Quesada JL, Benítez S, et al. Electronegative LDL from normolipemic subjects induces IL-8 and monocyte chemotactic protein secretion by human endothelial cells. Arterioscler Thromb Vasc Biol. 2000;20:2281-2287.
8. Sánchez-Quesada JL, Camacho M, Antón R, et al. Electronegative LDL of FH subjects: chemical characterization and induction of chemokine release from human endothelial cells. Atherosclerosis. 2003;166:261-270.
9. Hodis HN, Kramsch DM, Avogaro P, et al. Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low-density lipoprotein (electronegative LDL). J Lipid Res. 1994;35:669-677.
10. Demuth K, Myara I, Chappey B, et al. A cytotoxic electronegative LDL subfraction is present in human plasma. Arterioscler Thromb Vasc Biol. 1996;16:773-783.
11. Blencowe C, Hermetter A, Kostner GM, et al. Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein(a) in comparison with low-density lipoprotein. J Biol Chem. 1995;270:31151-31157.
12. McCall MR, La Belle M, Forte TM, et al. Dissociable and nondissociable forms of platelet-activating factor acetylhydrolase in human plasma LDL: implications for LDL oxidative susceptibility. Biochem Biophys Acta. 1999;1437:23-36.
13. Serrar-Serrar J, Ordóñez-Llanos J, Serra-Grima R, et al. Marathon runners presented lower serum cholesteryl ester transfer activity than sedentary subjects. Atherosclerosis. 1993;101:43-49.
14. Marzal-Casacuberta A, Blanco-Vaca F, Ishida Y, et al. Functional lecithin: cholesterol acyltransferase deficiency and HDL deficiency in transgenic mice overexpressing human apolipoprotein A-II. J Biol Chem. 1996;271:6720-6728.
15. Sánchez-Quesada JL, Benítez S, Franco M, et al. Density distribution of electronegative LDL (LDL(-)) in normolipemic and hyperlipemic subjects. J Lipid Res. 2002;43:699-705.
16. Dentan C, Tselepis AD, Chapman MJ, et al. Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase. Biochim Biophys Acta. 1996;1299:353-357.
17. Karabina SAP, Liapikos TA, Grekas G, et al. Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subfractions. Biochim Biophys Acta. 1994;1213:34-38.
18. Sevanian A, Hwang J, Hodis HN, et al. Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arterioscler Thromb Vasc Biol. 1996;16:784-793.
19. Stafforini DM, Tjoelker LW, McCormick SPA, et al. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low-density lipoprotein. J Biol Chem. 1999;274:7018-7024.
20. Yamada Y, Stafforini DM, Imaizumi T, et al. Characterization of the platelet-activating factor acetylhydrolase from human plasma by heterologous expression in Xenopus laevis oocytes. Proc Natl Acad Sci U S A. 1994;91:10320-10324.
21. Stafforini DM, McIntyre TM, Carter E, et al Human plasma platelet-activating factor acetylhydrolase: association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem. 1987;262:4215-4222.
22. Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase: purification and properties. J Biol Chem. 1987;262:4223-4230.
23. Tew DG, Southan C, Rice SQJ, et al. Purification, properties, sequencing and cloning of a lipoprotein-associated serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins. Arterioscler Thromb Vasc Biol. 1996;16:591-599.
24. Sevanian A, Bittolo-Bon G, Cazzolato G, et al. Electronegative LDL is a lipid hydroperoxide-enriched circulating lipoprotein. J Lipid Res. 1997;38:419-428.
25. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A. 1998;85:2805-2809.
26. Carpenter KLH, Dennis IF, Challis IR, et al. Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. FEBS Lett. 2001;505:357-363.
27. Takahara N, Kashiwagi A, Maegawa H, et al. Lysophosphatidylcholine stimulates the expression and production of MCP-1 by human vascular endothelial cells. Metabolism. 1996;45:559-564.
28. Navab M, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001;21:481-488.
29. Theilmeier G, de Geest B, van Veldholden PP, et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/-mice. FASEB J. 2000;14:2023-2039.
30. Tsimihodimos V, Karabina SAP, Tambaki AP, et al. Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res. 2002;43:256-263.